SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) saw some unusual options trading activity on Monday. Investors purchased 42,324 call options on the stock. This is an increase of approximately 54% compared to the average volume of 27,474 call options.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several hedge funds have recently made changes to their positions in SLS. Larson Financial Group LLC purchased a new stake in shares of SELLAS Life Sciences Group in the fourth quarter valued at $26,000. Beacon Pointe Advisors LLC acquired a new stake in SELLAS Life Sciences Group in the 4th quarter worth about $38,000. Concurrent Investment Advisors LLC purchased a new stake in SELLAS Life Sciences Group in the 4th quarter valued at about $38,000. Money Concepts Capital Corp acquired a new position in shares of SELLAS Life Sciences Group during the 4th quarter valued at about $40,000. Finally, CWM LLC lifted its holdings in shares of SELLAS Life Sciences Group by 124.7% during the 4th quarter. CWM LLC now owns 11,782 shares of the company’s stock worth $44,000 after acquiring an additional 6,538 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

SELLAS Life Sciences Group Price Performance

SELLAS Life Sciences Group stock opened at $4.50 on Tuesday. The stock has a market capitalization of $640.98 million, a P/E ratio of -16.07 and a beta of 2.27. SELLAS Life Sciences Group has a 12-month low of $0.95 and a 12-month high of $5.18. The firm’s 50-day moving average is $3.71 and its two-hundred day moving average is $2.44.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.